MX2019010394A - Composiciones y metodos para mejorar la funcion sexual. - Google Patents
Composiciones y metodos para mejorar la funcion sexual.Info
- Publication number
- MX2019010394A MX2019010394A MX2019010394A MX2019010394A MX2019010394A MX 2019010394 A MX2019010394 A MX 2019010394A MX 2019010394 A MX2019010394 A MX 2019010394A MX 2019010394 A MX2019010394 A MX 2019010394A MX 2019010394 A MX2019010394 A MX 2019010394A
- Authority
- MX
- Mexico
- Prior art keywords
- sexual function
- compositions
- methods
- improving sexual
- male
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B7/00—Electrically-operated teaching apparatus or devices working with questions and answers
- G09B7/06—Electrically-operated teaching apparatus or devices working with questions and answers of the multiple-choice answer-type, i.e. where a given question is provided with a series of answers and a choice has to be made from the answers
- G09B7/10—Electrically-operated teaching apparatus or devices working with questions and answers of the multiple-choice answer-type, i.e. where a given question is provided with a series of answers and a choice has to be made from the answers wherein a set of answers is common to a plurality of questions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Theoretical Computer Science (AREA)
- Educational Technology (AREA)
- General Physics & Mathematics (AREA)
- Business, Economics & Management (AREA)
- Educational Administration (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Las modalidades incluyen métodos para mejorar la función sexual en un hombre con hiperplasia prostática benigna (HPB), mediante el uso de composiciones que contienen compuestos basados en péptidos pequeños y un vehículo aceptable farmacéuticamente. El método incluye, pero no se limita a, la administración de los compuestos por vía intramuscular, por vía oral, por vía intravenosa, por vía intraprostática, por vía intratecal, por vía intratumoral, por vía intranasal, por vía tópica, por vía transdérmica, etcétera, ya sea solos o conjugados con un portador, a un hombre que lo necesite.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/446,406 US10335453B2 (en) | 2017-03-01 | 2017-03-01 | Compositions and methods for improving sexual function |
| PCT/US2018/017349 WO2018160335A1 (en) | 2017-03-01 | 2018-02-08 | Compositions and methods for improving sexual function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019010394A true MX2019010394A (es) | 2019-10-14 |
Family
ID=61274349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019010394A MX2019010394A (es) | 2017-03-01 | 2018-02-08 | Composiciones y metodos para mejorar la funcion sexual. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10335453B2 (es) |
| EP (1) | EP3576772B1 (es) |
| JP (1) | JP7061132B2 (es) |
| KR (1) | KR102249021B1 (es) |
| CN (1) | CN110381984B (es) |
| AU (1) | AU2018227345B2 (es) |
| BR (1) | BR112019018197A2 (es) |
| CA (1) | CA3054169C (es) |
| MX (1) | MX2019010394A (es) |
| NZ (1) | NZ756851A (es) |
| RU (1) | RU2739916C1 (es) |
| WO (1) | WO2018160335A1 (es) |
| ZA (1) | ZA201905609B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200360466A1 (en) * | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11298400B2 (en) * | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US11278588B2 (en) * | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| BR102020010933A2 (pt) * | 2020-05-29 | 2021-12-14 | Edson Luiz Peracchi | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento de disfunção erétil e hiperplasia prostática benigna |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3423507A (en) | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4329364A (en) | 1974-09-11 | 1982-05-11 | Schering Corporation | Antiandrogenic agents and methods for the treatment of androgen dependent disease states |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE2817157A1 (de) | 1978-04-17 | 1979-10-25 | Schering Ag | Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie |
| FR2465486A1 (fr) | 1979-09-21 | 1981-03-27 | Roussel Uclaf | Nouvelle application utilisant la lh-rh ou des agonistes |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3121153A1 (de) | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
| US4457489A (en) | 1981-07-13 | 1984-07-03 | Gilmore Samuel E | Subsea fluid conduit connections for remote controlled valves |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4659695A (en) | 1985-02-08 | 1987-04-21 | Fernand Labrie | Method of treatment of prostate cancer |
| US4775660A (en) | 1984-08-02 | 1988-10-04 | Fernand Labrie | Treatment of breast cancer by combination therapy |
| US4760053A (en) | 1984-08-02 | 1988-07-26 | Fernand Labrie | Combination therapy for selected sex steroid dependent cancers |
| CA2006332C (en) | 1988-12-21 | 2003-04-08 | Suzanne De La Monte | Method of detecting neurological disease or dysfunction |
| US5948634A (en) | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| JPH06256387A (ja) | 1991-06-14 | 1994-09-13 | Suetsuna Yoko | 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤 |
| WO1994023756A1 (en) | 1993-04-20 | 1994-10-27 | The General Hospital Corporation | Neural thread protein gene expression and detection of alzheimer's disease |
| MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
| CA2251691A1 (en) | 1996-03-26 | 1997-10-02 | Razvan T. Radulescu | Peptides with antiproliferative properties |
| JP4194664B2 (ja) | 1997-02-26 | 2008-12-10 | ザ ジェネラル ホスピタル コーポレイション | アルツハイマー病の処置または予防のために効果的な薬物をスクリーニングするためのトランスジェニック動物および細胞株 |
| WO1999019347A1 (en) | 1997-10-10 | 1999-04-22 | Astrazeneca Ab | Synthetic genes with immunomodulatory effects |
| US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
| CA2353797A1 (en) | 1998-12-11 | 2000-06-15 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| WO2000058339A2 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| CA2364630A1 (en) | 1999-03-12 | 2000-09-21 | Human Genome Sciences, Inc. | 50 human secreted proteins |
| CA2365223A1 (en) | 1999-03-19 | 2000-09-28 | Craig A. Rosen | 46 human secreted proteins |
| EP1171462A2 (en) | 1999-03-26 | 2002-01-16 | Human Genome Sciences, Inc. | 49 human secreted proteins |
| AU3769700A (en) | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| CN1300779A (zh) | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸 |
| EP1307488A2 (en) | 2000-06-26 | 2003-05-07 | Millennium Pharmaceuticals, Inc. | A human calcium channel protein and uses thereof |
| US7259232B1 (en) | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| CA2325666A1 (fr) | 2000-12-01 | 2002-06-01 | Institut Pasteur | Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques |
| US6783969B1 (en) | 2001-03-05 | 2004-08-31 | Nuvelo, Inc. | Cathepsin V-like polypeptides |
| DE60222745T2 (de) | 2001-03-08 | 2008-07-10 | Nymox Pharmaceutical Corp., St. Laurent | Verwendung von neurofilamentproteinen zur behandlung von tumoren |
| DE60224231D1 (de) | 2001-05-16 | 2008-01-31 | Nymox Corp | Prävention des Zelltodes durch Verwendung von Segmenten der Neurofilamentproteinen |
| NZ529911A (en) | 2001-05-25 | 2008-05-30 | Nymox Corp | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| BR0211199A (pt) | 2001-07-19 | 2004-10-26 | Nymox Corp | Peptìdeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| WO2005113720A2 (en) | 2004-05-19 | 2005-12-01 | Auburn University | A strategy for designing patient-specific anti-cancer drugs |
| KR20080076961A (ko) * | 2005-12-20 | 2008-08-20 | 화이자 프로덕츠 인크. | Ｐｄｅ５ 억제제 및 무스카린성 길항제를 포함하는ｌｕｔｓ의 치료를 위한 약제학적 조합물 |
| CA2643239A1 (en) | 2006-03-10 | 2007-09-20 | Nymox Corporation | Method of preventing or reducing the risk or incidence of cancer using neural thread protein based peptides |
| US20080027005A1 (en) * | 2006-07-31 | 2008-01-31 | Paul Averback | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US9243035B2 (en) | 2013-11-26 | 2016-01-26 | Nymox Corporation | Peptides effective in the treatment of conditions requiring the removal or destruction of cells |
| US20160215031A1 (en) | 2015-01-27 | 2016-07-28 | Nymox Pharnaceutical Corporation | Method of treating disorders requiring destruction or removal of cells |
| JP6256387B2 (ja) | 2015-03-09 | 2018-01-10 | 株式会社豊田自動織機 | 電動圧縮機 |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
-
2017
- 2017-03-01 US US15/446,406 patent/US10335453B2/en active Active
-
2018
- 2018-02-08 RU RU2019128059A patent/RU2739916C1/ru active
- 2018-02-08 MX MX2019010394A patent/MX2019010394A/es unknown
- 2018-02-08 EP EP18707189.9A patent/EP3576772B1/en active Active
- 2018-02-08 AU AU2018227345A patent/AU2018227345B2/en not_active Ceased
- 2018-02-08 CA CA3054169A patent/CA3054169C/en active Active
- 2018-02-08 BR BR112019018197-0A patent/BR112019018197A2/pt unknown
- 2018-02-08 WO PCT/US2018/017349 patent/WO2018160335A1/en active Search and Examination
- 2018-02-08 JP JP2019545753A patent/JP7061132B2/ja active Active
- 2018-02-08 KR KR1020197028642A patent/KR102249021B1/ko active IP Right Grant
- 2018-02-08 NZ NZ756851A patent/NZ756851A/en not_active IP Right Cessation
- 2018-02-08 CN CN201880015223.1A patent/CN110381984B/zh active Active
-
2019
- 2019-08-26 ZA ZA2019/05609A patent/ZA201905609B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3576772A1 (en) | 2019-12-11 |
| US20180250355A1 (en) | 2018-09-06 |
| WO2018160335A1 (en) | 2018-09-07 |
| US10335453B2 (en) | 2019-07-02 |
| ZA201905609B (en) | 2021-05-26 |
| KR20190121368A (ko) | 2019-10-25 |
| CA3054169C (en) | 2024-04-30 |
| RU2739916C1 (ru) | 2020-12-29 |
| NZ756851A (en) | 2022-07-29 |
| AU2018227345B2 (en) | 2020-06-25 |
| JP7061132B2 (ja) | 2022-04-27 |
| CN110381984B (zh) | 2023-11-28 |
| BR112019018197A2 (pt) | 2020-07-28 |
| KR102249021B1 (ko) | 2021-05-10 |
| CN110381984A (zh) | 2019-10-25 |
| CA3054169A1 (en) | 2018-09-07 |
| EP3576772B1 (en) | 2021-09-22 |
| AU2018227345A1 (en) | 2019-09-19 |
| JP2020510003A (ja) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019010394A (es) | Composiciones y metodos para mejorar la funcion sexual. | |
| NZ738853A (en) | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations | |
| EP4275688A3 (en) | Method of ameliorating or preventing the worsening or the progression of symptoms of bph | |
| MX2018012564A (es) | Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata. | |
| MX2021005767A (es) | Composiciones de nanoemulsiones que tienen una permeabilidad mejorada. | |
| MX2018014202A (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos. | |
| MY192088A (en) | Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| PE20091205A1 (es) | Anticuerpo anti-receptor de il-6 | |
| BR112012031297A2 (pt) | formulações de spray oral e métodos para administração de sildenafil | |
| ECSP003847A (es) | Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco | |
| HN2003000100A (es) | Compuestos utiles en terapia | |
| AU2018337752A1 (en) | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents | |
| MY193138A (en) | Stable liquid gonadotropin formulation | |
| WO2016125190A3 (en) | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof | |
| AR096355A1 (es) | Composición odontológica de papaína en gel para el tratamiento atraumático de caries y método para prepararla | |
| WO2018106794A3 (en) | Compositions and methods relating to molecular cerium-oxide nanoclusters | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2019001209A (es) | Metodo para evitar o reducir la incidencia de la retencion urinaria aguda. | |
| ZA202108521B (en) | Method of improving lower urinary tract symptoms | |
| TWD190461S (zh) | 中性電極之部分 | |
| MX2022013116A (es) | Tensioactivos polianiónicos y métodos de preparacion y uso de los mismos. | |
| MX2022013178A (es) | Tensioactivos polianiónicos y métodos de preparación y uso de los mismos. | |
| MX2022013179A (es) | Tensioactivos polianiónicos, y métodos de preparación y uso de los mismos. | |
| MX2022013113A (es) | Tensioactivos polianiónicos y métodos de preparacion y uso de los mismos. | |
| Lan | The Trend of Indo-Pacific Strategy and its Impact on the US-Japan Alliance——Creating and evolving of dual ambiguity, dual assurance and dual check strategies |